Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III study of subcutaneous efgartigimod PH20 in adults with bullous pemphigoid
CTR20222928Phase 3Completed
- Sponsor
- argenx
- Start
- Jun 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of efgartigimod alfa in Bullous Pemphigoid (BP), sponsored by argenx. Started Jun 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on CTR20222928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222928.